Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Basal Insulin, GLP-1RA, GLP-1RA + Basal Feb 01 | 2023Novo Nordisk Q4 ’22 Earnings UpdatePurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, SGLT2i Jan 31 | 2023Pfizer Q4 ’22 Earnings; Lilly Initiates Open-Label SURPASS-SWITCH-2 Study; Fractyl Health Announces Positive Week 24 REVITA-T2Di Data; Sciwind Initiates Dosing for Ph3 Ecnoglutide Trials in China; Lifescan Announces Publication of Connected BGM RWEPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, SGLT2i Jan 27 | 2023Viatris’s Generic Dapagliflozin and Lilly’s Trulicity Pediatric Extension Receive Positive CHMP opinions; Medtronic’s Wearable Partner Files for Bankruptcy; Nemaura Looks to Raise Additional CapitalPurchase Blast
$599
Posted in: Glucose Monitoring, Other Jan 26 | 2023Diabetes Research Institute Appoints Matthias von Herrath as Scientific Director; Nemaura Receives First proBEAT Purchase Order from HealthFleetPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Jan 25 | 2023Abbott Q4 ’22 Earnings; Tidepool Loop Receives FDA Clearance; Lilly to Expand Incretin Manufacturing Capacity; Novo Receives Marketing Practices Complaint; AGC Biologics to Manufacture Tzield; Nemaura Reports Positive Miboko Data; J&J Q4 ’22 Earnings; and Embecta Opens New HeadquartersPurchase Blast
$599
Posted in: Insulin Delivery, Other, SGLT2i Jan 23 | 2023Another Branded SGLT2i Approved by FDA; Tandem Completes AMF Medical Acquisition; January CHMP AgendaPurchase Blast
$599
Posted in: SGLT2i Jan 20 | 2023Jardiance CKD sNDA Accepted by FDA Without Priority ReviewPurchase Blast
$599
Posted in: Other Jan 19 | 2023FDA Accepts OCA NASH NDA; Palatin Initiates Ph2b DKD TrialPurchase Blast
$599
Posted in: DPP-IVi, Other Jan 18 | 2023Diamyd Initiates Ph2 Trial in At-risk Individuals; Teladoc Cuts 300 Jobs; Merck to Resolve Sitagliptin Contamination IssuePurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other Jan 13 | 2023Rybelsus Approved as First-Line Therapy for T2DM; Biocon Receives Another CRL; Tandem Initiates Control-IQ 2.0 Feasibility Study in T1DMPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Insulin Delivery, Other Jan 12 | 2023JPM 2023 Day 4: TNDM, ICPT, LXRX, MNKD, and XERS; Oramed Discontinues Ph3 Development ORMD-0801 in T2DM; Versanis Initiates Ph2b Obesity Trial EnrollmentPurchase Blast$599
Posted in: Insulin Delivery, Other Jan 11 | 2023JPM 2023 Day 3: ESPR, IONS, EMBC, AMRN, and VTRSPurchase Blast$599
Posted in: GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Jan 10 | 2023JPM 2023 Day 2: LLY, ABT, PODD, SNY, AZN, MRK, and GSK; Sernova Advances T1DM Cell Pouch Technology; Pfizer Initiates New Ph1 Oral GLP-1RA TrialPurchase Blast$599
Posted in: Glucose Monitoring, Other Jan 09 | 2023JPM 2023 Day 1: DXCM, MDT, PFE, AMGN, VRTX, NVS, CYTK, TDOC, ARWR, and AMGN; AZ Acquires CinCor; Viking Completes Ph2b NASH Enrollment; Ionis Sells Pelacarsen RoyaltiesPurchase Blast
$599
Posted in: Other Jan 06 | 2023Madrigal Announces Additional Positive MAESTRO-NASH Data; Bluebird Sells Second PRV to BMS for $95MPurchase Blast
$599
Posted in: Other Jan 05 | 2023Inventiva Updates Lanifibranor NASH Development Program; Galectin Completes Ph2b/3 NAVIGATE Study Enrollment; Novo Signs Stemcell Deal with FujifilmPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other Jan 04 | 2023Holiday Hangover: Novo's Wegovy/Ozempic Featured on 60 Minutes; Intercept OCA NASH NDA Refiled; Amgen Initiates Ph2 AMG 133 Obesity Trial; Steven Russell Joins Beta Bionics; Novo’s Third Cagrisema Ph3 Trial Initiated; Wegovy Pediatric Indication; Lannett Bs-Insulin Updates; Equillium and Metacrine Terminate Merger; and MorePurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA + Basal, Other Dec 22 | 2022Lilly Initiates Final Ph3 QWINT Trial; Madrigal Announces $300M+ in Financing Events to Advance Resmetirom; Akebia Receives Interim Response to Appeal for Vadadustat CRLPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other Dec 21 | 2022Medtronic InPen App Recall; Libre 3 + Ypsomed AID Available in Germany; Altimmune Positive Pemvidutide NAFLD Data; Embecta CY Q3 ’22 Earnings Update; Alnylam Submits ALN-KHK CTA for T2DM; Biocorp Receives EU Medical Device CertificationPurchase Blast
$599
Posted in: Basal Insulin, Other, SGLT2i Dec 19 | 2022Madrigal Wins Big with Ph3 NASH Data; Novo Expands Partnership for Dose Check; AZ Announces DELIVER Positive CHMP OpinionPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
